Trials / Completed
CompletedNCT01799473
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 98 (actual)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.
Conditions
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-02-26
- Last updated
- 2015-03-24
Locations
52 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01799473. Inclusion in this directory is not an endorsement.